Clinical characteristics, diagnosis, treatment, and prognosis of Atezolizumab-induced encephalitis, aseptic meningitis or meningoencephalitis

Clinical characteristics, diagnosis, treatment, and prognosis of Atezolizumab-induced encephalitis, aseptic meningitis or meningoencephalitis

ObjectiveImmune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and expanded the range of tumor indications. However, as the usage of this medication has increased, related adverse events are increasingly being identified. Among these, Atezolizumab-induced encephalitis, aseptic men...

Full description

Saved in:

Bibliographic Details
Main Authors:	Qingzi Yan, Yixiang Hu, Xiang Liu, Hong Xia
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Human Neuroscience
Subjects:	atezolizumab PD-L1 encephalitis immune checkpoint inhibitor aseptic meningitis meningoencephalitis
Online Access:	https://www.frontiersin.org/articles/10.3389/fnhum.2025.1443463/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical Features and Predictors of Lethal Outcome in Tick-Borne Encephalitis: A Retrospective Study from Lithuania
by: G. Rynkevič, et al.
Published: (2024-02-01)

Unexpected cause of headache in a patient with Noonan syndrome: aseptic meningitis
by: Hacer Efnan Melek Arsoy, et al.
Published: (2024-09-01)

An unusual cause of recurrent meningitis in a 17-year-old girl
by: K Nikitha, et al.
Published: (2020-01-01)

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
by: Parissa Tabrizian, et al.
Published: (2025-02-01)

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
by: Meng Wu, et al.
Published: (2025-02-01)

Severe Cases of Tick-Borne Encephalitis in Northeastern Poland
by: Justyna Adamczuk, et al.
Published: (2024-12-01)

J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan
by: Eisaku Miyauchi, MD, PhD, et al.
Published: (2025-03-01)

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison
by: Wei Chen, et al.
Published: (2025-01-01)

Comparison of positive BioFire FilmArray meningitis/encephalitis (ME) panels, CSF cultures, CSF parameters, clinical presentation and in-patient mortality among patients with bacterial and fungal meningitis
by: Thein Myint, et al.
Published: (2025-02-01)

Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis
by: Jie Dai, et al.
Published: (2025-01-01)

Treatment of neuro-invasive listeriosis: an overview
by: P. Gudeikaitė, et al.
Published: (2018-12-01)

Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials
by: Ji Ren, et al.
Published: (2025-01-01)

PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer
by: Jiacheng Li, et al.
Published: (2025-01-01)

Autoimmune pancerebellitis as an immune-related adverse event: an illustrative case
by: D. Valančius, et al.
Published: (2021-12-01)

Inosine enhances the efficacy of immune‐checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study
by: Haiqing Zhao, et al.
Published: (2024-09-01)

Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease
by: Ayaka Hayashi, et al.
Published: (2025-01-01)

Clinical Features and Rehabilitation Needs in Patients with Neuroinvasive West Nile Virus Infection: A Retrospective Analysis in an Area of High Incidence
by: Maria Chiara Maccarone, et al.
Published: (2025-01-01)

Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy
by: Hironori Ochi, et al.
Published: (2025-01-01)

Efficacy and safety of immune checkpoint inhibitors in patients with advanced intrahepatic cholangiocarcinoma
by: Ziting Peng, et al.
Published: (2025-02-01)

Aseptic breast abscess syndrome as an example of neutrophilic dermatosis. Can an immune defect be the reason of a disease?
by: Przemysław Borowy, et al.
Published: (2024-11-01)

Neoadjuvant chemoradiotherapy up-regulates PD-L1 in radioresistant colorectal cancer
by: Sung Uk Bae, et al.
Published: (2025-03-01)

Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01)

Glutamine-glutamate centered metabolism as the potential therapeutic target against Japanese encephalitis virus-induced encephalitis
by: Mengyuan Li, et al.
Published: (2025-01-01)

Meningoencephalitis by Cryptococcus. Case presentation
by: Idalmis Reyes Rodríguez, et al.
Published: (2016-12-01)

Evaluating The Effect of Time and Temperature on The Ph, Titratable Acidity &Brix of Pasteurized LowTo-No Nectar Orange Drinks Packed in Paper Based Aseptic Packages
by: Azeen Kamal Al-Deen Mohammad, et al.
Published: (2022-06-01)

Assessment of clinical prognosis in autoimmune encephalitis: Girona score
by: Gary Álvarez Bravo, et al.
Published: (2025-01-01)

Review of the aetiologies of central nervous system infections in Vietnam
by: Hannah E. Brindle, et al.
Published: (2025-01-01)

Uncovering the role of tumor cGAS expression in predicting response to PD-1/L1 inhibitors in non-small cell lung cancer
by: Yuichi Ozawa, et al.
Published: (2024-11-01)

Electrochemical sensors for the detection of immune checkpoint related proteins and their role in cancer companion diagnostics
by: Louise Barnaby, et al.
Published: (2025-03-01)

Machine-Learning Parsimonious Prediction Model for Diagnostic Screening of Severe Hematological Adverse Events in Cancer Patients Treated with PD-1/PD-L1 Inhibitors: Retrospective Observational Study by Using the Common Data Model
by: Seok Jun Park, et al.
Published: (2025-01-01)

Immunomediated Encephalitis: New Diagnoses on the Neurology–Psychiatry Interface
by: Daniel Damiani, et al.

Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma
by: Atsushi Naganuma, et al.
Published: (2025-01-01)

COVID-19 infection: neurological symptoms and encephalitis
by: A. Jasionis, et al.
Published: (2020-06-01)

Three effective cases of transcatheter arterial embolization after atezolizumab and bevacizumab treatment for hepatocellular carcinoma: a case report
by: Koji Rinka, et al.
Published: (2025-01-01)

Varicella Zoster Virus-induced Acute Retinal Necrosis Following Acute Meningoencephalitis in a Patient with Presumed COVID-19
by: Kiana Hassanpour, et al.
Published: (2024-12-01)

Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study
by: Ping Zhou, et al.
Published: (2024-12-01)

Clinical features of autonomic dysfunction in children with anti-N-methyl-D aspartic receptor encephalitis
by: Dongqing Li, et al.
Published: (2025-01-01)

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
by: Shang‐Gin Wu, et al.
Published: (2025-01-01)

Tick-borne encephalitis: students’ attitude and knowledge analysis
by: R. Mineikytė, et al.
Published: (2018-06-01)

Efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy in advanced KRAS-mutant non-small cell lung cancer
by: Huiping Qiang, et al.
Published: (2025-03-01)